Humacyte (HUMA) Non-Current Assets (2020 - 2026)
Humacyte (HUMA) posted quarterly Non-Current Assets of $47.0 million for Q1 2026, down 47.15% year-over-year from $88.8 million in Q1 2025, and down 3.32% quarter-over-quarter from $48.6 million in Q4 2025.
Humacyte (HUMA) Non-Current Assets (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Non-Current Assets for 7 consecutive years, with $47.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 47.15% year-over-year to $47.0 million; the TTM figure through Mar 2026 stood at $232.8 million (down 25.59% YoY), while the FY2025 annual figure was $48.6 million, down 46.04% from the prior year.
- Non-Current Assets retreated to $47.0 million in Q1 2026 per HUMA's latest filing, from $48.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $91.8 million in Q3 2024 and bottomed at $42.2 million in Q2 2024.
- Historically, Non-Current Assets has averaged $58.1 million across 5 years, with a median of $50.1 million in 2022.
- Annual changes were most pronounced in 2025 — Non-Current Assets soared 106.46% — and 2026, when it tumbled 47.15%.
- Humacyte's Non-Current Assets stood at $50.1 million in 2022, then decreased by 10.28% to $44.9 million in 2023, then jumped by 100.27% to $90.0 million in 2024, then sank by 46.04% to $48.6 million in 2025, then dropped by 3.32% to $47.0 million in 2026.
- Business Quant data shows HUMA's Non-Current Assets at $47.0 million in Q1 2026, $48.6 million in Q4 2025, and $50.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Humacyte | 155.45 Mn | 155.45 Mn | -825,000.00 | 45.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.30 Mn |
| Mar 31, 2026 | 46.96 Mn |
| Dec 31, 2025 | 48.57 Mn |
| Sep 30, 2025 | 50.16 Mn |
| Jun 30, 2025 | 87.07 Mn |
| Mar 31, 2025 | 88.85 Mn |
| Dec 31, 2024 | 90.01 Mn |
| Sep 30, 2024 | 91.76 Mn |
| Jun 30, 2024 | 42.17 Mn |
| Mar 31, 2024 | 43.54 Mn |
| Dec 31, 2023 | 44.95 Mn |
| Sep 30, 2023 | 46.53 Mn |
| Jun 30, 2023 | 47.54 Mn |
| Mar 31, 2023 | 49.12 Mn |
| Dec 31, 2022 | 50.09 Mn |
| Sep 30, 2022 | 51.61 Mn |
| Jun 30, 2022 | 53.34 Mn |
| Mar 31, 2022 | 55.17 Mn |
| Dec 31, 2021 | 57.19 Mn |
| Sep 30, 2021 | 59.18 Mn |